As we previously reported, Genentech filed a complaint against Amgen in the District of Delaware seeking declaratory judgment that Amgen has violated the patent dance provisions of the BPCIA in connection with its proposed biosimilar version of Genentech’s Avastin® product by failing to provide manufacturing information beyond its aBLA and by unreasonably refusing to allow Genentech to show its experts Amgen’s aBLA.
Yesterday, Genentech filed a motion for speedy hearing that seeks expedited resolution of the action before March 22, 2017 because “Genentech faces a deadline of March 24 to identify the patents it can assert against Amgen’s proposed biosimilar, and its failure to identify all such patents as a result of Amgen’s statutory violation may forever preclude Genentech from fully vindicating its Avastin® patent rights.”
Stay tuned for more updates from Big Molecule Watch.
